Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 — PANCOLIN  

Covid19 Clinical Trial

Official title: Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19

Status Not yet recruiting

Clinical Trial Summary

Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known.

The investigators will explore patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected.

The investigators will determine whether this persistance varies according to

• the severity of the Covid-19

• a treatment by steroids during the covid-19. This will help to anticipate whether a second wave of infection is possible in a non-naive population.

Clinical Trial Description

Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known.

The investigators will explore adult patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected.

The investigators will determine whether this persistance varies according to

• the severity of the Covid-19 (3 groups: no oxyegn therapy; oxygen therapy of less than 3L/min; oxygen therapy of 3L/min or more)

• a treatment by steroids during the covid-19. Immunocompromised patients will be excluded. ;

Related Conditions & MeSH terms

• Covid19

• NCT number: NCT04543006
• Study type: Interventional
• Source: University Hospital, Grenoble
• Contact: Olivier Epaulard, MD,PhD
• Phone: 0033476765291
• Email: oepaulard@chu-grenoble.fr
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 8, 2020
• Completion date: December 31, 2021